Core Viewpoint - The revised Implementation Regulations of the Drug Administration Law of the People's Republic of China will take effect on May 15, 2026, aiming to enhance drug research, production, and safety management in the pharmaceutical industry [1][2]. Group 1: Drug Research and Registration - The regulations support drug development and innovation based on clinical value, encouraging the research and creation of new drugs [1] - A fast-track registration process for drug market entry is established, along with clear re-registration procedures and mechanisms for converting prescription drugs to over-the-counter status [1] - Special market exclusivity is granted for pediatric medications and treatments for rare diseases, along with data protection for drugs containing novel chemical components [1] Group 2: Drug Production Management - The regulations enforce strict management of commissioned drug production, clarifying the responsibilities of drug market license holders during the commissioning process [1] - Specific management requirements for the production and sale of traditional Chinese medicine pieces and formula granules are outlined [1] Group 3: Drug Operation and Usage - The regulations improve the management system for online drug sales, holding third-party platforms accountable for drug transactions [1] - Enhanced pharmaceutical management in medical institutions is mandated to ensure drug quality during usage [1] - Approval processes for the preparation of formulations in medical institutions are specified, supporting the preparation of pediatric formulations to meet the needs of child patients [1] Group 4: Drug Safety Supervision - The regulations clarify drug safety supervision and inspection measures, detailing the process for quality sampling and testing [2] - Strict legal responsibilities are established for violations, ensuring accountability within the pharmaceutical sector [2]

Group 1 - The core viewpoint emphasizes the importance of strict supervision and management of narcotic and psychotropic drugs to prevent illegal distribution [1][2][3] - The provincial drug regulatory authority is enhancing the review of production demand plans and increasing inspections of key drug varieties [2][3] - There is a focus on establishing a comprehensive safety management system for special drugs within enterprises [2][3] Group 2 - The "Clear Source and Cut Off - 2025" initiative aims to include designated enterprises dealing with narcotic and psychotropic drugs in the annual inspection list [3] - Joint efforts with the provincial health commission are being made to ensure compliance in the handling of fentanyl-related products [3] - The province has not experienced any incidents of narcotic drug leakage in recent years [3] Group 3 - Extensive training and educational campaigns are being conducted to raise awareness about new regulations regarding narcotic drug management [4] - Enterprises are targeted as key areas for education, with on-site training for employees on drug abuse management and legal regulations [4] - The use of themed promotional activities, such as Drug Safety Awareness Week and International Day Against Drug Abuse, aims to enhance public awareness and community cooperation [4]

Core Viewpoint - The report from Zhonghang Securities indicates that the pharmaceutical and biotechnology industry is expected to benefit in the long term from ongoing bulk procurement of drugs and medical supplies, with a focus on innovative drugs and high-end medical devices [1][6]. Industry Overview - In 2024, the pharmaceutical and biotechnology industry is projected to achieve operating revenue of 24,657.41 billion yuan, a year-on-year decline of 0.97% [1]. - The net profit attributable to the parent company is expected to be 1,405.71 billion yuan, down 12.97% year-on-year, showing improvement compared to the 2023 growth rate of -18.90% [1]. - The largest revenue segments in 2024 are expected to be pharmaceutical commerce (10,179.60 billion yuan), chemical preparations (4,472.88 billion yuan), and traditional Chinese medicine (3,539.45 billion yuan) [1]. Subsector Performance - In 2024, the chemical pharmaceutical, medical device, and pharmaceutical commerce sectors are expected to see positive revenue growth rates of 4.20%, 1.41%, and 0.78% respectively [2]. - The chemical preparation segment is projected to grow by 4.43%, while the medical device segment is expected to see an 8.40% increase in medical consumables [2]. - Conversely, the vaccine sector is anticipated to decline by 37.77% due to high base effects from previous public health events [2]. Profitability Metrics - The gross margin for the pharmaceutical and biotechnology industry in 2024 is expected to be 32.58%, a decrease of 0.53 percentage points from 2023 [4]. - The net profit margin is projected to be 5.99%, down 0.77 percentage points from the previous year [4]. - The sales expense ratio has been steadily declining, from 17.07% in 2018 to 13.33% in 2024, influenced by centralized procurement and medical insurance negotiations [4][5]. Innovation and Policy Support - The government has reinforced the strategic importance of innovative drugs through various policy measures, including the "Implementation of Innovative Drug Industry Promotion Project" and the establishment of an innovative drug catalog system [6][7]. - The domestic innovative drug sector is becoming increasingly competitive, with the highest number of innovative drug research pipelines globally and a rapid increase in clinical trial numbers [6][7]. - The report highlights that high-quality innovative drug companies are entering a profitability cycle, supported by improved research and development capabilities [7].